|
US4733665C2
(en)
|
1985-11-07 |
2002-01-29 |
Expandable Grafts Partnership |
Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
|
|
US5135919A
(en)
|
1988-01-19 |
1992-08-04 |
Children's Medical Center Corporation |
Method and a pharmaceutical composition for the inhibition of angiogenesis
|
|
DE3827340A1
(de)
*
|
1988-08-12 |
1990-02-15 |
Hoechst Ag |
Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen
|
|
JPH0291023U
(enExample)
|
1989-01-05 |
1990-07-19 |
|
|
|
US5441944A
(en)
|
1989-04-23 |
1995-08-15 |
The Trustees Of The University Of Pennsylvania |
Substituted cyclodextrin sulfates and their uses as growth modulating agents
|
|
US5071957A
(en)
|
1989-08-04 |
1991-12-10 |
Bristol-Myers Company |
Antibiotic BU-4061T
|
|
US4990448A
(en)
|
1989-08-04 |
1991-02-05 |
Bristol-Myers Company |
Bu-4061T
|
|
KR0166088B1
(ko)
|
1990-01-23 |
1999-01-15 |
. |
수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
|
|
US5376645A
(en)
|
1990-01-23 |
1994-12-27 |
University Of Kansas |
Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
|
|
HUT62312A
(en)
|
1990-03-05 |
1993-04-28 |
Cephalon Inc |
Process for producing chymotrypsin-like proteases and their inhibitors
|
|
US5340736A
(en)
|
1991-05-13 |
1994-08-23 |
The President & Fellows Of Harvard College |
ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
|
|
GB9300048D0
(en)
|
1993-01-04 |
1993-03-03 |
Wellcome Found |
Endothelin converting enzyme inhibitors
|
|
TW380137B
(en)
|
1994-03-04 |
2000-01-21 |
Merck & Co Inc |
Process for making an epoxide
|
|
US5693617A
(en)
|
1994-03-15 |
1997-12-02 |
Proscript, Inc. |
Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
|
|
US6660268B1
(en)
|
1994-03-18 |
2003-12-09 |
The President And Fellows Of Harvard College |
Proteasome regulation of NF-KB activity
|
|
US6506876B1
(en)
|
1994-10-11 |
2003-01-14 |
G.D. Searle & Co. |
LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use
|
|
US6083903A
(en)
|
1994-10-28 |
2000-07-04 |
Leukosite, Inc. |
Boronic ester and acid compounds, synthesis and uses
|
|
DE19505263A1
(de)
|
1995-02-16 |
1996-08-22 |
Consortium Elektrochem Ind |
Verfahren zur Reinigung von wasserlöslichen Cyclodextrinderivaten
|
|
US6335358B1
(en)
|
1995-04-12 |
2002-01-01 |
President And Fellows Of Harvard College |
Lactacystin analogs
|
|
US6150415A
(en)
|
1996-08-13 |
2000-11-21 |
The Regents Of The University Of California |
Epoxide hydrolase complexes and methods therewith
|
|
AU4499697A
(en)
|
1996-09-13 |
1998-04-02 |
New York University |
Method for treating parasitic diseases with proteasome inhibitors
|
|
CZ298749B6
(cs)
|
1996-10-18 |
2008-01-16 |
Vertex Pharmaceuticals Incorporated |
Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem
|
|
EP1136498A1
(en)
|
1996-10-18 |
2001-09-26 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases, particularly hepatitis c virus NS3 protease
|
|
US6046177A
(en)
|
1997-05-05 |
2000-04-04 |
Cydex, Inc. |
Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
|
|
US5874418A
(en)
|
1997-05-05 |
1999-02-23 |
Cydex, Inc. |
Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
|
|
US6133248A
(en)
|
1997-06-13 |
2000-10-17 |
Cydex, Inc. |
Polar drug of prodrug compositions with extended shelf-life storage and a method of making thereof
|
|
US6133308A
(en)
|
1997-08-15 |
2000-10-17 |
Millennium Pharmaceuticals, Inc. |
Synthesis of clasto-lactacystin beta-lactone and analogs thereof
|
|
US6075150A
(en)
|
1998-01-26 |
2000-06-13 |
Cv Therapeutics, Inc. |
α-ketoamide inhibitors of 20S proteasome
|
|
US6099851A
(en)
|
1998-06-02 |
2000-08-08 |
Weisman; Kenneth M. |
Therapeutic uses of leuprolide acetate
|
|
US6902721B1
(en)
|
1998-07-10 |
2005-06-07 |
Osteoscreen, Inc. |
Inhibitors of proteasomal activity for stimulating bone growth
|
|
US6462019B1
(en)
|
1998-07-10 |
2002-10-08 |
Osteoscreen, Inc. |
Inhibitors of proteasomal activity and production for stimulating bone growth
|
|
US6838436B1
(en)
|
1998-07-10 |
2005-01-04 |
Osteoscreen Inc. |
Inhibitors of proteasomal activity for stimulating bone growth
|
|
US6204257B1
(en)
|
1998-08-07 |
2001-03-20 |
Universtiy Of Kansas |
Water soluble prodrugs of hindered alcohols
|
|
NZ511197A
(en)
|
1998-10-20 |
2003-08-29 |
Millenium Pharmaceuticals Inc |
Method for monitoring proteasome inhibitor drug action
|
|
US6492333B1
(en)
|
1999-04-09 |
2002-12-10 |
Osteoscreen, Inc. |
Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
|
|
US6831099B1
(en)
|
1999-05-12 |
2004-12-14 |
Yale University |
Enzyme inhibition
|
|
JP2003528039A
(ja)
|
1999-10-20 |
2003-09-24 |
オステオスクリーン，インコーポレイテッド |
骨および毛成長を刺激するためのプロテアソーム活性のインヒビター
|
|
EP2301565A1
(de)
|
2000-10-12 |
2011-03-30 |
ViroLogik GmbH |
Verwendung von Proteasome Hemmern zur Behandlung von Virus-Infektionen
|
|
DK3078667T3
(en)
|
2001-01-25 |
2019-01-07 |
The United States Of America Represented By The Sec Dep Of Health And Human Services |
Formulation of boric acid compounds
|
|
ES2278049T3
(es)
|
2001-05-21 |
2007-08-01 |
Alcon, Inc. |
Uso de inhibidores de proteasoma para tratar trastornos de ojo seco.
|
|
CN100415770C
(zh)
*
|
2001-05-30 |
2008-09-03 |
诺瓦提斯公司 |
2－{[n－(2－氨基－3－(杂芳基或芳基)丙酰基)－氨基酰基]－氨基}－烷基硼酸衍生物
|
|
EP1463719A2
(en)
|
2002-01-08 |
2004-10-06 |
Eisai Co., Ltd |
Eponemycin and epoxomicin analogs and uses thereof
|
|
US20040116329A1
(en)
|
2002-01-29 |
2004-06-17 |
Epstein Stephen E. |
Inhibition of proteasomes to prevent restenosis
|
|
WO2003086283A2
(en)
|
2002-04-09 |
2003-10-23 |
Greenville Hospital System |
Metastasis modulating activity of highly sulfated oligosaccharides
|
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
US7902185B2
(en)
|
2002-06-03 |
2011-03-08 |
Als Therapy Development Foundation, Inc. |
Treatment of neurodegenerative diseases using proteasome modulators
|
|
US20030224469A1
(en)
|
2002-06-03 |
2003-12-04 |
Buchholz Tonia J. |
Methods and kits for assays utilizing fluorescence polarization
|
|
WO2004010937A2
(en)
|
2002-07-26 |
2004-02-05 |
Advanced Research & Technology Institute At Indiana University |
Method of treating cancer
|
|
US7189740B2
(en)
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
|
TW200418791A
(en)
|
2003-01-23 |
2004-10-01 |
Bristol Myers Squibb Co |
Pharmaceutical compositions for inhibiting proteasome
|
|
BRPI0409250B8
(pt)
|
2003-04-08 |
2022-01-18 |
Mitsubishi Pharma Corp |
Composições farmacêuticas sólidas compreendendo um agonista receptor de s1p e um álcool do açúcar
|
|
JP4653103B2
(ja)
|
2003-06-10 |
2011-03-16 |
ザ ジェイ．ディヴィッド グラッドストン インスティテューツ |
レンチウイルス感染症を治療するための方法
|
|
US7012063B2
(en)
|
2003-06-13 |
2006-03-14 |
Children's Medical Center Corporation |
Reducing axon degeneration with proteasome inhibitors
|
|
CA2552641A1
(en)
|
2003-12-31 |
2005-07-21 |
Cydex, Inc. |
Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
|
|
GB0400804D0
(en)
|
2004-01-14 |
2004-02-18 |
Innoscience Technology Bv |
Pharmaceutical compositions
|
|
US7232818B2
(en)
|
2004-04-15 |
2007-06-19 |
Proteolix, Inc. |
Compounds for enzyme inhibition
|
|
US8129346B2
(en)
|
2004-04-15 |
2012-03-06 |
Onyx Therapeutics, Inc. |
Compounds for enzyme inhibition
|
|
US8198270B2
(en)
|
2004-04-15 |
2012-06-12 |
Onyx Therapeutics, Inc. |
Compounds for proteasome enzyme inhibition
|
|
ES2510840T3
(es)
|
2004-05-10 |
2014-10-21 |
Onyx Therapeutics, Inc. |
Compuestos para la inhibición enzimática del proteosoma
|
|
WO2005111009A2
(en)
|
2004-05-10 |
2005-11-24 |
Proteolix, Inc. |
Synthesis of amino acid keto-epoxides
|
|
EP2100899A3
(en)
|
2004-10-20 |
2009-09-30 |
Proteolix, Inc. |
Compounds for proteasome enzyme inhibition
|
|
WO2006063154A1
(en)
|
2004-12-07 |
2006-06-15 |
Proteolix, Inc. |
Composition for proteasome inhibition
|
|
US7468383B2
(en)
*
|
2005-02-11 |
2008-12-23 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
|
EP1863513A2
(en)
|
2005-03-11 |
2007-12-12 |
The University of North Carolina at Chapel Hill |
Potent and specific immunoproteasome inhibitors
|
|
US7998938B2
(en)
|
2005-04-15 |
2011-08-16 |
Geron Corporation |
Cancer treatment by combined inhibition of proteasome and telomerase activities
|
|
GT200600350A
(es)
|
2005-08-09 |
2007-03-28 |
|
Formulaciones líquidas
|
|
US8716322B2
(en)
|
2005-11-09 |
2014-05-06 |
Onyx Therapeutics, Inc. |
Compounds for enzyme inhibition
|
|
AR057227A1
(es)
|
2005-12-09 |
2007-11-21 |
Centocor Inc |
Metodo para usar antagonistas de il6 con inhibidores del proteasoma
|
|
US20070207950A1
(en)
|
2005-12-21 |
2007-09-06 |
Duke University |
Methods and compositions for regulating HDAC6 activity
|
|
WO2007122686A1
(ja)
|
2006-04-14 |
2007-11-01 |
Eisai R & D Management Co., Ltd. |
ベンズイミダゾール化合物
|
|
DE102006026464A1
(de)
|
2006-06-01 |
2007-12-06 |
Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma |
Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
|
|
NZ597545A
(en)
|
2006-06-19 |
2013-07-26 |
Proteolix Inc |
Peptide epoxyketones for proteasome inhibition
|
|
WO2008033807A2
(en)
|
2006-09-13 |
2008-03-20 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Synergistic combinations of antineoplastic thiol-binding mitochondrial oxidants and antineoplastic proteasome inhibitors for the treatment of cancer
|
|
AU2008209555A1
(en)
|
2007-01-23 |
2008-07-31 |
Gloucester Pharmaceuticals, Inc. |
Combination therapy comprising romidepsin and I.A. bortezomib
|
|
WO2008140782A2
(en)
|
2007-05-10 |
2008-11-20 |
Proteolix, Inc. |
Compounds for enzyme inhibition
|
|
MY161991A
(en)
|
2007-08-06 |
2017-05-31 |
Millennium Pharm Inc |
Proteasome inhibitors
|
|
US7442830B1
(en)
|
2007-08-06 |
2008-10-28 |
Millenium Pharmaceuticals, Inc. |
Proteasome inhibitors
|
|
JP5734656B2
(ja)
|
2007-10-04 |
2015-06-17 |
オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
ペプチドエポキシケトンプロテアーゼ阻害剤結晶及びアミノ酸ケトエポキシドの調製
|
|
US7838673B2
(en)
|
2007-10-16 |
2010-11-23 |
Millennium Pharmaceuticals, Inc. |
Proteasome inhibitors
|
|
JP5600595B2
(ja)
|
2007-10-16 |
2014-10-01 |
ミレニアム ファーマシューティカルズ， インコーポレイテッド |
プロテアソーム阻害剤
|
|
WO2009067453A1
(en)
|
2007-11-19 |
2009-05-28 |
Syndax Pharmaceuticals, Inc. |
Combinations of hdac inhibitors and proteasome inhibitors
|
|
DK2730581T3
(en)
|
2008-06-17 |
2016-08-15 |
Millennium Pharm Inc |
Boronate Ester Compounds and Pharmaceutical Compositions thereof.
|
|
AR075090A1
(es)
|
2008-09-29 |
2011-03-09 |
Millennium Pharm Inc |
Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
|
|
EA024364B1
(ru)
|
2008-10-21 |
2016-09-30 |
Оникс Терапьютикс, Инк. |
Способ лечения множественной миеломы
|
|
TWI504598B
(zh)
|
2009-03-20 |
2015-10-21 |
Onyx Therapeutics Inc |
結晶性三肽環氧酮蛋白酶抑制劑
|
|
CN101928329B
(zh)
*
|
2009-06-19 |
2013-07-17 |
北京大学 |
三肽硼酸(酯)类化合物、其制备方法和应用
|
|
WO2011060179A1
(en)
|
2009-11-13 |
2011-05-19 |
Onyx Therapeutics, Inc |
Use of peptide epoxyketones for metastasis suppression
|
|
CA2791651C
(en)
|
2010-03-01 |
2019-08-20 |
Onyx Therapeutics, Inc. |
Compounds for immunoproteasome inhibition
|
|
AU2011235227B2
(en)
|
2010-03-31 |
2016-09-08 |
Millennium Pharmaceuticals, Inc. |
Derivatives of 1-amino-2-cyclopropylethylboronic acid
|
|
EP2555621A4
(en)
|
2010-04-07 |
2014-07-02 |
Onyx Therapeutics Inc |
CRYSTALLINE EPOXYCETONE PEPTIDE IMMUNOPROTEASOME INHIBITOR
|
|
FR2962092B1
(fr)
*
|
2010-06-30 |
2013-06-28 |
Valeo Systemes Dessuyage |
Adaptateur d'essuie-glace a contacts electriques
|